In support of this notion, a number of studies [124, 125, 132, 136, 164–166] indicate therapeutic benefits of testosterone by ameliorating the EAE-severity or clinical remissions in MS patients that are accompanied with increased gray matter volume, reduced Th1/Th17 inflammatory cytokines (IFN-γ, IL-2, and IL-17A), skewness of Th1/Th17:Treg ratio toward Tregs, shift of immune response toward Th2 type (IL-10), increased NK cell populations, and significant reductions in CNS infiltrations containing CD4 T cells [124, 125, 132, 135, 164, 165, 167]. This evidence concerns the gene CD4 and myeloid sarcoma.